Hubei Biocause Pharmaceutical Co., Ltd.

000627.SZ

000627.SZHubei Biocause Pharmaceutical Co., Ltd. CN flag

Shenzhen

3.11

CNY

-0.19

(-5.76%)

-0.17EPS

-18.29P/E

17.09BMarket Cap

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

CNE000000F48

Return %

Stock

S&P500

0.97

32.83

-11.14

33.33

-56.01

95.62

Use logarithmic scale

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	0.84	0.59	0.72	0.58	0.79	4.2	12.08	6.3	10.17	8.52	10.53	10.86	9.91	9.18
Basic EPS, GAAP	-0.08	0.01	-0.08	0.06	0.18	0.44	0.3	0.27	0.36	0.12	0.1	0.06	-0.13	-0.17
Free Cash Flow per Basic Share	-0.06	-0.03	-0.01	-0.22	-0.06	-1.49	-0.08	2.99	5.65	4.37	0.83	1.62	1.89	-0.01
Dividend per Share	0.02	0.02	0.02	0.02	0.02	0.03	0.03	0.06	0.05	0.13	0.08	0.15	0.28	0.17
Book Value per Share	0.94	0.98	0.92	0.94	1.12	1.53	1.83	1.87	2.18	2.24	2.39	2.51	2.04	2
Tangible Book Value per Share	0.76	0.88	0.78	0.71	0.94	3.38	4.52	3.99	5.69	5.83	6.59	6.15	5.42	5.45
Basic Weighted Avg Shares	1,356	1,314	1,347	1,397	1,374	4,043	4,421	4,913	4,933	4,836	4,707	4,568	5,014	4,938
Sales/Revenue/Turnover	1,134	780	968	806	1,085	16,990	53,406	30,951	50,192	41,200	49,583	49,616	49,699	45,324
Operating Margin (%)	-5.14	-4.79	-8.6	-11.68	42.81	50.47	45.9	85.94	22.62	8.68	64.2	62.48	43.68	23.47
Depreciation Expense	63	52	69	74	65	139	123	93	79	64	134	147	152	- -
Net Income, GAAP	-102	12	-101	84	247	1,779	1,326	1,327	1,776	580	471	274	-652	-829
Effective Tax Rate (%)	- -	7.94	- -	22.79	25.09	9.43	1.69	9.83	19.68	22.87	- -	- -	- -	- -
Profit Margin (%)	-8.97	1.52	-10.44	10.39	22.8	10.47	2.48	4.29	3.54	1.41	0.95	0.55	-1.31	-1.83
Working Capital	235	35	-266	-184	-134	15,925	17,107	23,307	17,351	43,727	37,299	30,992	26,204	18,215
LT Debt	123	23	- -	- -	42	360	40	110	- -	2,830	6,204	6,878	7,171	5,569
Total Equity	1,414	1,537	1,418	1,490	1,784	20,398	26,705	26,015	34,353	34,588	37,475	34,603	33,634	33,375
Return on Invested Capital (%)	- -	-1.86	- -	-3.86	17.32	63.87	85.02	73.15	25.38	6.66	- -	- -	- -	- -
Return on Capital (%)	- -	2.1	- -	6.01	14.13	5.44	-0.14	1.25	2.48	0.14	- -	- -	- -	- -
Return on Common Equity (%)	-7.69	0.93	-8.02	6.57	17.32	46.08	18.59	15.36	17.8	5.37	4.26	2.41	-6.01	-8.05

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	172.14%	12.97%	0.17%
Net Income, GAAP	17.4%	-86.38%	-337.82%
Free Cash Flow	459.65%	20.4%	28.12%
Total Cash Common Dividend	77.99%	57.03%	102.03%
Total Equity	112.73%	6.12%	-2.8%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Ms. Wenxia Zhou
Full Time Employees: 1,765
Sector: Financial Services
Industry: Insurance - Life
Address: #122 Yangwan Road Jingmen People's Republic of China 448000
IPO Date: Nov 12, 1996
Website: biocause.com
Similar Companies: Hansard Global plc (HSD.L)
PT Paninvest Tbk (PNIN.JK)
Mercuries Life Insurance Company Ltd. (2867.TW)
Power Corporation of Canada (POW.TO)
Brighthouse Financial, Inc. (BHFAN)
Asia Financial Holdings Limited (0662.HK)
Business: Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. The company also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, it is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride. The company exports its products to the United States, the European Union, and internationally. Hubei Biocause Pharmaceutical Co., Ltd. is based in Jingmen, China.

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	0.84	0.59	0.72	0.58	0.79	4.2	12.08	6.3	10.17	8.52	10.53	10.86	9.91	9.18
Basic EPS, GAAP	-0.08	0.01	-0.08	0.06	0.18	0.44	0.3	0.27	0.36	0.12	0.1	0.06	-0.13	-0.17
Free Cash Flow per Basic Share	-0.06	-0.03	-0.01	-0.22	-0.06	-1.49	-0.08	2.99	5.65	4.37	0.83	1.62	1.89	-0.01
Dividend per Share	0.02	0.02	0.02	0.02	0.02	0.03	0.03	0.06	0.05	0.13	0.08	0.15	0.28	0.17
Book Value per Share	0.94	0.98	0.92	0.94	1.12	1.53	1.83	1.87	2.18	2.24	2.39	2.51	2.04	2
Tangible Book Value per Share	0.76	0.88	0.78	0.71	0.94	3.38	4.52	3.99	5.69	5.83	6.59	6.15	5.42	5.45
Basic Weighted Avg Shares	1,356	1,314	1,347	1,397	1,374	4,043	4,421	4,913	4,933	4,836	4,707	4,568	5,014	4,938
Sales/Revenue/Turnover	1,134	780	968	806	1,085	16,990	53,406	30,951	50,192	41,200	49,583	49,616	49,699	45,324
Operating Margin (%)	-5.14	-4.79	-8.6	-11.68	42.81	50.47	45.9	85.94	22.62	8.68	64.2	62.48	43.68	23.47
Depreciation Expense	63	52	69	74	65	139	123	93	79	64	134	147	152	- -
Net Income, GAAP	-102	12	-101	84	247	1,779	1,326	1,327	1,776	580	471	274	-652	-829
Effective Tax Rate (%)	- -	7.94	- -	22.79	25.09	9.43	1.69	9.83	19.68	22.87	- -	- -	- -	- -
Profit Margin (%)	-8.97	1.52	-10.44	10.39	22.8	10.47	2.48	4.29	3.54	1.41	0.95	0.55	-1.31	-1.83
Working Capital	235	35	-266	-184	-134	15,925	17,107	23,307	17,351	43,727	37,299	30,992	26,204	18,215
LT Debt	123	23	- -	- -	42	360	40	110	- -	2,830	6,204	6,878	7,171	5,569
Total Equity	1,414	1,537	1,418	1,490	1,784	20,398	26,705	26,015	34,353	34,588	37,475	34,603	33,634	33,375
Return on Invested Capital (%)	- -	-1.86	- -	-3.86	17.32	63.87	85.02	73.15	25.38	6.66	- -	- -	- -	- -
Return on Capital (%)	- -	2.1	- -	6.01	14.13	5.44	-0.14	1.25	2.48	0.14	- -	- -	- -	- -
Return on Common Equity (%)	-7.69	0.93	-8.02	6.57	17.32	46.08	18.59	15.36	17.8	5.37	4.26	2.41	-6.01	-8.05

	Dec'23	Mar'24	Jun'24
Total Current Assets	50,666	44,632	35,297
Accounts Receivable, Net	77	103	107
Cash, Cash Equivalents & STI	29,952	23,028	13,487
Inventories	4,132	4,295	4,357
Total Current Liabilities	24,462	23,537	17,082
Payables & Accruals	- -	- -	- -
ST Debt	18,248	16,588	10,930
Deferred Revenue	- -	- -	- -

	Dec'23	Mar'24	Jun'24
ST Debt	18,248	16,588	10,930
LT Borrowings	7,099	7,206	5,510
LT Finance Leases	72	54	59
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	4,941	4,941	4,941
Market Capitalization	12,838	12,198	8,642

Year	Q1	Q2	Q3	Q4	FY
2022	18,215	9,385	10,229	11,786	49,616
2023	21,928	11,505	7,756	8,511	49,699
2024	17,487	11,571	- -	- -	- -

Hubei Biocause Pharmaceutical Co., Ltd.

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Working Capital

Capital Structure

Quarterly Earnings Per Share

Year

Quarterly Revenue

Year

Quarterly Dividends Per Share

Year